Maze Therapeutics, Inc. (MAZE) Institutional Ownership

Ownership Summary

Maze Therapeutics, Inc. (NASDAQ:MAZE) appears in 137 institutional 13F filings for the quarter ending December 2025.

• They owned 104.9% of outstanding stock in December 2025, up from 93.8% the prior quarter.
• Their total shares held in MAZE increased 13.6% quarter over quarter, and separately, investors owning Maze Therapeutics stayed flat from a year ago.
• Activity in MAZE broke down as 98 buyers, 21 sellers, and 18 unchanged among 137 total holders.
• In total, institutional investors held 48.02Mn shares in Maze Therapeutics as of December 2025, up by 5.75Mn shares quarter on quarter, and with no net change year over year.
• As of December 31, 2025, Janus Henderson Group Plc held the largest stake in Maze Therapeutics with 5.72Mn shares, accounting for 12.49% of total shares outstanding.
• Leading buyers of Maze Therapeutics shares for the quarter ending December 2025 were Paradigm Biocapital Advisors LP (2.74Mn), Janus Henderson Group Plc (2.58Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.44Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.18Mn), Cormorant Asset Management, LP (750.0K).
• Top sellers of MAZE stock for the quarter ending December 2025 included Deep Track Capital, LP (768.88K), MARSHALL WACE, LLP (536.83K), Woodline Partners LP (385.0K), Foresite Capital Management IV, LLC (365.76K), ADAR1 Capital Management, LLC (308.97K).
• According to Business Quant data, leading holders of MAZE for December 2025 are Janus Henderson Group Plc (5.72Mn), Frazier Life Sciences Management, L.P. (4.57Mn), TRV GP IV, LLC (4.47Mn), ARCH Venture Management, LLC (4.12Mn), Deep Track Capital, LP (3.48Mn), Paradigm Biocapital Advisors LP (2.74Mn), BlackRock, Inc. (2.57Mn), a16z Capital Management, L.L.C. (1.7Mn), Venrock Adviser, LLC (1.6Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.44Mn).